Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics

Molecular Psychiatry

Volumn 10, Issue 9, 2005, Pages 877-883

  Seeman, P ^a,b   Ko, F ^a   Tallerico, T ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Domperidone; Dopamine receptor; Ketamine; NMDA receptors; Phencyclidine; Psychotomimetics

Indexed keywords

DIZOCILPINE; DOMPERIDONE; DOPAMINE 2 RECEPTOR; KETAMINE; LYSERGIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE; PSYCHEDELIC AGENT; TRITIUM; AMINO ACID RECEPTOR BLOCKING AGENT; CARRIER PROTEIN; DIZOCILPINE MALEATE; DOPAMINE; DOPAMINE TRANSPORTER; MEMBRANE PROTEIN; NERVE PROTEIN;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISSOCIATION CONSTANT; DRUG POTENCY; DRUG RECEPTOR BINDING; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; ANIMAL; CHO CELL; CORPUS STRIATUM; DRUG EFFECT; HAMSTER; KINETICS; METABOLISM; MOLECULAR CLONING; PHYSIOLOGY;

ANIMALS; CHO CELLS; CLONING, MOLECULAR; CORPUS STRIATUM; CRICETINAE; DIZOCILPINE MALEATE; DOMPERIDONE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; EXCITATORY AMINO ACID ANTAGONISTS; KETAMINE; KINETICS; LYSERGIC ACID DIETHYLAMIDE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; PHENCYCLIDINE; RATS; RECEPTORS, DOPAMINE D2;

EID: 25644458208     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4001682     Document Type: Article

References (39)

1. Van Rossum JM. The significance of dopamine-receptor blockade for the action of neuroleptic drugs. In: Brill H, Cole J, Deniker P, Hippius H, Bradley PB (eds). Neuropsychopharmacology, Proceedings of the 5th Collegium Internationale Neuropsychopharmacologicum. Excerpta Medica Foundation: Amsterdam, 1967, pp 321-329.
2. Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987; 1: 133-152.
3. Tamminga CA, Holcom HH, Gao X-M, Lahti AC. Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. Int Clin Psychopharmacol 1995; 10(Suppl 3): 29-37.
4. Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1999; 20: 201-225.
5. Goff DC, Coyle JT. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiat 2001; 158: 1367-1377.
6. Lozovsky D, Saller CF, Bayorh MA, Chiueh CC, Rice KC, Burke Jr TR et al. Effects of phencyclidine on rat prolactin, dopamine receptor and locomotor activity. Life Sci 1983; 32: 2725-2731.
7. Mele A, Wozniak KM, Hall FS, Pert A. The role of striatal dopaminergic mechanisms in rotational behavior induced by phencyclidine and phencyclidine-like drugs. Psychopharmacology (Berl) 1998; 135: 107-118.
8. Kapur S, Seeman P. NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors - implications for models of schizophrenia. Mol Psychiat 2002; 7: 837-844.
9. Seeman P. Comment on 'Diverse psychotomimetics act through a common signaling pathway'. Science 2004; 305: 180.
10. 2 receptors in rat and human striatal tissues. Synapse 2003; 47: 250-254.
11. Seeman P, Niznik HB, Guan HC, Booth G, Ulpian C. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci USA 1989; 86: 10156-10160.
12. Seeman P, Sunahara RK, Niznik HB. Receptor-receptor link in membranes revealed by ligand competition: example for dopamine D1 and D2 receptors. Synapse 1994; 17: 62-64.
13. George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. The functional state of the dopamine receptor in the anterior pituitary is in the high-affinity form. Endocrinology 1985; 117: 690-697.
14. Lee FJ, Xue S, Pei L, Vukusic B, Chery N, Wang Y et al. Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 2002; 111: 219-230.
15. Pei L, Lee FJ, Moszczynska A, Vukusic B, Liu F. Regulation of dopamine D1 receptor function by physical interaction with the NMDA receptors. J Neurosci 2004; 24: 1149-1158.
16. Salter MW. D1 and NMDA receptors hook up: expanding on an emerging theme. Trends Neurosci 2003; 26: 235-237.
17. 3H]spiperone in isotonic medium. Implications for human positron emission tomography. Synapse 2003; 49: 209-215.
18. Liu IS, George SR, Seeman P. The human dopamine D2(Longer) receptor has a high-affinity state and inhibits adenylyl cyclase. Mol Brain Res 2000; 77: 281-284.
19. 3H-spiperone depend on tissue concentration: analysis and examples. J Neurochem 1984; 43: 221-235.
20. Seeman P, Watanabe M, Grigoriadis D, Tedesco JL, George SR, Svensson U et al. Dopamine D2 receptor binding sites for agonists. A tetrahedral model. Mol Pharmacol 1985; 28: 391-399.
21. Grigoriadis D, Seeman P. Complete conversion of brain D2dopamine receptors from the high- to the low-affinity state for dopamine agonists, using sodium ions and guanine nucleotide. J Neurochem 1985; 44: 1925-1935.
22. Svenningsen P, Nomikos GG, Greengard P. Response to comment on 'Diverse psychotomimetics act through a common signaling pathway'. Science 2004; 305: 180.
23. 2 dopaminergic receptors and it potentiates dopamine-mediated prolactin secretion in lactotrophs in vitro. Life Sci 1998; 63: 215-222.
24. Meltzer HY, Fessler RG, Simonovic M, Doherty J, Fang VS. Lysergic acid diethylamide: evidence for stimulation of pituitary dopamine receptors. Psychopharmacology (Berl) 1977; 54: 39-44.
25. Meltzer HY, Simonovic M, Gudelsky GA. Phencyclidine-induced inhibition of rat prolactin secretion: increased portal blood dopamine. Eur J Pharmacol 1985; 110: 143-146.
26. Pampillo M, Theas S, Duvilanski B, Seilicovich A, Lasaga M. Effect of ionotropic and metabotropic glutamate agonists and D-aspartate on prolactin release from anterior pituitary cells. Exp Clin Endocrinol Diabetes 2002; 110: 138-144.
27. Login IS. Direct stimulation of pituitary release by glutamate. Life Sci 1990; 47: 2269-2275.
28. Giannini AJ, Eighan MS, Loiselle RH, Giannini MC. Comparison of haloperidol and chlorpromazine in the treatment of phencyclidine psychosis. J Clin Pharmacol 1984; 24: 202-204.
29. Giannini AJ, Nageotte C, Loiselle RH, Malone DA, Price WA. Comparison of chlorpromazine, haloperidol and pimozide in the treatment of phencyclidine psychosis: DA-2 receptor specificity. J Toxicol Clin Toxicol 1984-85; 22: 573-579.
30. Giannini AJ, Underwood NA, Condon M. Acute ketamine intoxication treated by haloperidol: a preliminary study. Am J Ther 2000; 7: 389-391.
31. Krystal JH, D'Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) 1999; 145: 193-204.
32. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiat 1991; 148: 1301-1308.
33. 3H]MK-SOl binding to NMDA receptors in vivo and in vitro. Eur J Pharmacol 2000; 137: 263-270.
34. Grimwood S, Le Bourdelles BL, Atack JR, Barton C, Cockett W, Cook SM et al. Generation and characterization of stable cell lines expressing recombinant human N-methyl-D-aspartate receptor subtypes. J Neurochem 1996; 66: 2239-2247.
35. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiat 2002; 47: 27-38.
36. Ögren SO, Goldstein M. Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated. Neuropsychopharmacology 1994; 11: 167-177.
37. Reynolds IJ, Miller RJ. Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. Br J Pharmacol 1988; 95: 95-102.
38. 3H-raclopride. Biochem Pharmacol 1985; 34: 2251-2259.
39. Hall H, Sällemark M, Jerning E. Effects of remoxipride and some related new substituted salicylamides on rat brain receptors. Acta pharmacol toxicol 1986; 58: 61-70.